ArticleScientific reports2025
Jurkat T-cell lines exhibit marked genomic instability affecting karyotype, mutational profile, gene expression, immunophenotype and function.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Synergistic Induction of Caspase-8-Mediated Leukaemic Cell Death by Fisetin and Pinocembrin.International journal of molecular sciences · 2026Article
- CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL.International journal of molecular sciences · 2026Article
- A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products.International journal of pharmaceutics: X · 2026Article
- Phosphotyrosine proteomics reveals novel Zap70 and Itk pathway targets downstream of TCR and CAR in Jurkat T cells.Scientific reports · 2026Article
- Identification of novel DNA sequence motifs that modulate transcription in T cells.BMC genomics · 2026Article
- Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.Biomolecules & therapeutics · 2026Review
- Combined exposure to emergingFrontiers in toxicology · 2026Article
- From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia GravisEndocrine, metabolic & immune disorders drug targets · 2026Article
- Article
- A high-throughput chemotaxis assay for assessing immunotoxicity using multiple human immune cell types.NAM journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Jurkat cell line, derived from a case of T-cell lymphoblastic leukaemia, is widely employed as a model T-cell for biomedical research, including for the preclinical characterisation of cellular therapies such as chimeric antigen receptor T-cells. Here, we characterised genomic, transcriptomic, and functional features of Jurkat clone E6-1 cells from three different laboratories and compared these with Jurkat E6-1 cells from the American Type Culture Collection (ATCC). We identified marked karyotypic heterogeneity both between and within Jurkat E6-1 populations, confirmed through chromosomal microarray. Whole exome sequencing of each cell population revealed both shared and unique mutational profiles, and transcriptomic profiles varied markedly between Jurkat E6-1 cell populations. Finally, the Jurkat E6-1 cell populations exhibited substantial variations in immunophenotype and cytokine production, which were consistent with the genotypic and transcriptomic changes observed. In summary, we identify substantial genomic heterogeneity both between and within Jurkat E6-1 cell populations, highlighting the genomic instability of this line. These genomic changes were associated with differences in protein expression and cytokine production that may affect functional assays. Our findings highlight the importance of monitoring cell passage number, characterising cell lines, and replacing cell line stocks to assure the accuracy, reproducibility, and translatability of assays employing Jurkat E6-1 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.